Share |
News

Verisante Technology Inc., Lists on the OTCQX; Completes Stage 1 Audit Towards ISO Certification


May 26, 2011 at 2:00 pm

Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”) announced today that the Company will begin trading on the OTCQX International Tier as of the market opening on Thursday, May 26, 2011.  The OTCQX International is the premier tier of the US OTC market, home to many of the world's largest companies by market capitalization.

Verisante also announced that the Company has completed its Stage 1 Audit towards ISO 13485:2003 Certification and continues to prepare for obtaining Health Canada approval by the end of the year for its skin cancer detection device.


"As the Company moves towards Health Canada and European approval, we believe the time is right to enhance investor awareness of our Company and its unique technology through a listing on an important U.S. market,” said Thomas Braun, President and CEO, Verisante.


Investors can find current financial disclosure and real-time quotes for Verisante on www.otcqx.com and www.otcmarkets.com.  Investors can also find the Company’s corporate video and Zacks Investment Analyst reports on the Company’s website at www.verisante.com.


Hodgson Russ LLP will serve as Verisante’s Principal American Liaison on the OTCQX, responsible for providing guidance on OTCQX requirements.

About the OTC Markets Group

OTC Markets Group Inc. (OTCQX: OTCM) operates the world's largest electronic marketplace for broker-dealers to trade unlisted stocks.  Our OTC Link™ platform supports an open network of competing broker-dealers that provide investors with the best prices in over 10,000 OTC securities.  In 2010, securities on OTC Link traded over $144 billion in dollar volume, making it the third largest U.S. equity trading venue after NASDAQ and the New York Stock Exchange. We categorize the wide spectrum of OTC-traded companies into three tiers - OTCQX (the quality-controlled marketplace for investor friendly companies), OTCQB® (the U.S. reporting company marketplace for development stage companies), and OTC Pink™ (the speculative trading marketplace) - so investors can identify the level and quality of information companies provide.  To learn more about how OTC Markets Group makes the unlisted markets more transparent, informed, and efficient, visit www.otcmarkets.com.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was
 
developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate diagnostic results for many of the most common cancers to assist in the biopsy decision.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information contact:

Verisante Technology, Inc.
Thomas Braun, President & CEO   
Telephone: (604) 605-0507

Email: info@verisante.com
Website:  www.verisante.com
Youtube:  www.youtube.com/verisante
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top